ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRMD vs NVCT // RSI-14 & 200D SMA MOMENTUM

CorMedix Inc. (NASDAQ) VS. Nuvectis Pharma Inc. (NASDAQ) • 15-METRIC TALLY: CRMD 2 — NVCT 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: NVCT
rsi-technicals
25.3
rsi-technicals
41.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. NVCT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRMD NVCT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 45.50% -35.00% +80.50 CRMD /roic <GO>
EV/EBITDA & P/E Valuation 3.0x — — TIE /valuation <GO>
Free Cash Flow Yield — -2.64% — TIE /fcf-yield <GO>
Operating Margin 48.20% — — TIE /operating-margins <GO>
Net Profit Margin 52.30% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.81 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 CRMD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 25.3 41.3 -16.01 NVCT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 3.5x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $595.5M $605.6M -$10.1M NVCT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRMD REV NVCT REV CRMD GROSS % NVCT GROSS % CRMD FCF NVCT FCF
FY 2025 $311.7M $0 88.5% — $172.8M -$16.0M
FY 2024 $43.5M $0 92.7% — -$50.7M -$12.2M
FY 2023 $0 $0 — — -$38.4M -$16.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
NVCT // BETA —